Latest News

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Cantex’s azeliragon is an orally administered inhibitor of the receptor for advanced glycation end products (known as RAGE). Excessive activation of RAGE has been strongly implicated in life-threatening complications of COVID-19 infection, including lung and kidney failure. A protein produced by the immune system, known as “suPAR”, at high levels...

19 April, 2023

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Pharmaceuticals and Baptist Health Miami Cancer Institute, part of Baptist Health Cancer Care, the largest cancer program in South Florida, announced today that the U.S. Food and Drug Administration (FDA) has issued a “Study May Proceed” letter for the Miami Cancer Institute’s investigator initiated clinical trial to assess the...

06 March, 2023

Cantex Receives FDA “Study May Proceed” Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Cantex Pharmaceuticals announced the FDA issued a “Study May Proceed” letter for the Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy....

27 February, 2023

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma....

09 January, 2023

Cantex to Expand Development of Its Drug, Azeliragon, Collaborating with Harvard’s Wyss Institute, as a Treatment of COVID-19 and Other Inflammatory Lung Diseases

Cantex Pharmaceuticals, Inc. today announced that it has secured a global license from Harvard University's Office of Technology Development (OTD) to further develop Cantex's drug azeliragon into a treatment for inflammatory lung diseases including COVID-19....

24 February, 2022

Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.

WESTON, FL – September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.   About Cantex Pharmaceuticals Cantex Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on the transformation...

21 September, 2021

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

  HIGH POINT, N.C. and WESTON, FL– June 22, 2021 – vTv Therapeutics Inc. ("vTv", Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. ("Cantex") today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel antagonist of RAGE (the receptor...

22 June, 2021

Chimerix, Exclusive Worldwide Licensee of Cantex’s Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial

Cantex Pharmaceuticals, Inc. today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex’s DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI)...

26 February, 2021

Chimerix, Exclusive Licensee of Cantex’ Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19

Cantex Pharmaceuticals, Inc. today announced that Chimerix, Inc., to whom it licensed worldwide rights for the development and commercialization of its lead product, CX-01 (now known as DSTAT) has initiated a Phase 2/3 study of DSTAT in COVID-19 patients with acute lung injury (ALI)...

29 April, 2020

Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia

Chimerix (NASDAQ: CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. CX-01 has received Fast Track and Orphan Drug Designations...

31 July, 2019